NCT01592383View on ClinicalTrials.gov

Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2017

Study Completion Date

February 28, 2017

Conditions
Malignant Peritoneal Mesothelioma
Interventions
DRUG

erlotinib hydrochloride

Given PO

Trial Locations (1)

60637-1470

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT01592383 - Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma | Biotech Hunter | Biotech Hunter